Compass Therapeutics to Participate in Upcoming Investor Events
Compass Therapeutics (Nasdaq: CMPX), a clinical-stage oncology biopharmaceutical company, has announced its participation in two major healthcare investor conferences in November 2024. The company will present at the Stifel 2024 Healthcare Conference in New York on November 18 at 3:00 PM ET, and at the Jefferies London Healthcare Conference in London on November 21 at 2:00 PM GMT. Both presentations will be available via webcast and archived for 90 days on Compass' Events page.
Compass Therapeutics (Nasdaq: CMPX), un'azienda biofarmaceutica oncologica in fase clinica, ha annunciato la sua partecipazione a due importanti conferenze per investitori nel settore sanitario a novembre 2024. L'azienda presenterà alla Stifel 2024 Healthcare Conference a New York il 18 novembre alle 15:00 ET e alla Jefferies London Healthcare Conference a Londra il 21 novembre alle 14:00 GMT. Entrambe le presentazioni saranno disponibili tramite webcast e archiviate per 90 giorni nella pagina Eventi di Compass.
Compass Therapeutics (Nasdaq: CMPX), una empresa biofarmacéutica oncológica en etapa clínica, ha anunciado su participación en dos importantes conferencias de inversores en el sector de la salud en noviembre de 2024. La empresa presentará en la Stifel 2024 Healthcare Conference en Nueva York el 18 de noviembre a las 3:00 PM ET, y en la Jefferies London Healthcare Conference en Londres el 21 de noviembre a las 2:00 PM GMT. Ambas presentaciones estarán disponibles a través de webcast y archivadas durante 90 días en la página de Eventos de Compass.
컴파스 테라퓨틱스 (Nasdaq: CMPX), 임상 단계의 종양학 바이오 제약 회사가 2024년 11월에 열리는 두 개의 주요 건강 관리 투자자 회의에 참여한다고 발표했습니다. 이 회사는 11월 18일 오후 3시(ET)에 뉴욕에서 열리는 Stifel 2024 Healthcare Conference와 11월 21일 오후 2시(GMT)에 런던에서 열리는 Jefferies London Healthcare Conference에서 발표할 것입니다. 두 발표 모두 웹캐스트를 통해 제공되며 컴파스의 이벤트 페이지에서 90일 동안 아카이브됩니다.
Compass Therapeutics (Nasdaq: CMPX), une entreprise bio-pharmaceutique en oncologie en phase clinique, a annoncé sa participation à deux grandes conférences pour investisseurs dans le secteur de la santé en novembre 2024. L'entreprise présentera lors de la Stifel 2024 Healthcare Conference à New York le 18 novembre à 15h00 ET, et lors de la Jefferies London Healthcare Conference à Londres le 21 novembre à 14h00 GMT. Les deux présentations seront disponibles par webcast et archivées pendant 90 jours sur la page Événements de Compass.
Compass Therapeutics (Nasdaq: CMPX), ein biopharmazeutisches Unternehmen in der klinischen Phase, hat seine Teilnahme an zwei wichtigen Investorenkonferenzen im Gesundheitssektor im November 2024 bekannt gegeben. Das Unternehmen wird am 18. November um 15:00 Uhr ET auf der Stifel 2024 Healthcare Conference in New York präsentieren und am 21. November um 14:00 Uhr GMT auf der Jefferies London Healthcare Conference in London. Beide Präsentationen werden über einen Webcast verfügbar sein und 90 Tage lang auf der Veranstaltungsseite von Compass archiviert.
- None.
- None.
BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of November 2024.
Details are as follows:
Stifel 2024 Healthcare Conference
Location: New York, NY
Date: Monday, November 18, 2024
Time: 3:00pm ET
Webcast Link: https://wsw.com/webcast/stifel96/cmpx
Jefferies London Healthcare Conference
Location: London, UK
Date: November 21, 2024
Time: 2:00-2:25 PM GMT
Webcast Link: https://wsw.com/webcast/jeff315/cmpx
Virtual/Replay availability: Presentations will be archived for 90 days on Compass’ Events page.
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.
Investor Contact
ir@compasstherapeutics.com
Media Contact
Anna Gifford, Senior Manager of Communications
media@compasstherapeutics.com
617-500-8099
FAQ
When is Compass Therapeutics (CMPX) presenting at the Stifel Healthcare Conference 2024?
What time is Compass Therapeutics (CMPX) presenting at the Jefferies London Healthcare Conference?
How long will the Compass Therapeutics (CMPX) November 2024 conference presentations be available for replay?
